Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

This study is testing a drug called tarlatamab for people with extensive-stage small cell lung cancer (a type of aggressive lung cancer that has spread). Tarlatamab is a new type of cancer therapy designed to help the immune system find and attack cancer cells. **You may be eligible if...** - You are 18 years old or older - You have been newly diagnosed with extensive-stage small cell lung cancer, or you had limited-stage disease that came back more than 6 months after treatment - You are in good enough health to participate (ECOG performance status 0–2) **You may NOT be eligible if...** - Your cancer has not been confirmed by a pathology test (tissue or cell sample) - You are not well enough to tolerate treatment - You are under 18 years old Talk to your doctor to see if this trial is right for you.